Cancer survivors may experience more challenges to adopt a child
the ONA take:
According to a recent study published online ahead of print in the journal Cancer, researchers have found that cancer survivors' options for adoption may be limited by adoption agencies' policies.
Many young cancer survivors often opt to adopt to a child after cancer and cancer therapies leave some patients infertile; however, not only is adoption a long and costly process, but some adoption agencies also have policies that may prevent cancer survivors from being able to adopt.
For the study, oncology nurses participating in a training program contacted and interviewed adoption agencies about the costs and requirements for adoption. the nurses found that adoption fees ranged from $3,000 to $75,000. They also found that a few agencies believed it could be discouraging for a birth mother to have an adoptive parent with a history of cancer, while others reported that a history of cancer could make birth mothers feel optimistic and confident.
The study also helped oncology nurses to become more knowledgeable about the challenges of adoption in cancer survivors, and study authors hope that this experience will help them to better inform their patients on parenthood options in the future.
Researchers have found that cancer survivors' options for adoption may be limited by adoption agencies' policies.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
- Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|